FLT3 and acute myeloid leukemia: As for sorafenib, similarly limited single-agent antileukemic activity was observed in a phase 1 study evaluating sorafenib monotherapy in patients with relapsed/refractory FLT3-mutated AML (the study included two patients with other acute leukemias and a minority of patients without FLT3 mutations [22%]), in which only 10% of patients achieved CR or CR with incomplete platelet recovery [32].